Biosimilar Notices. (a) Upon Pfizer’s request any time after completion of the first Phase II Clinical Study for any Licensed Product, CytomX shall use reasonable efforts to assist and cooperate with Pfizer in establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and preparing submissions responsive to any Biosimilar Notices received by Pfizer; provided that Pfizer shall make the final decisions with respect to such strategy and any such responses.
Appears in 4 contracts
Samples: Option and License Agreement (CytomX Therapeutics, Inc.), Option and License Agreement (CytomX Therapeutics, Inc.), Option and License Agreement (CytomX Therapeutics, Inc.)
